CARACTERÍSTICAS DE LOS APARATOS

Qi tonic herbs help resolve phlegm and this helps move qi. This is true in cancer treatment and in pain management.

Eliminating or detoxifying herbs are bitter, cold and pungent and can injure gastrointestinal func- tion. They act in some ways just like chemother- apy or radiation.

Tonifying herbs are sweet and often sticky and can cause dampness. Dampness can be an under- lying mechanism for the proliferation of cancers. Therefore, care must be used in choosing herbs, accurately diagnosing the constitution, and under-

standing the overall environment in which one is hoping to work therapeutically.

Integrate Chinese with Western diagnostics and analysis. You must know more than classical Chinese medicine in order to treat cancer. This is especially true if you are working adjunctively alongside conventional medicine.

During chemotherapy the dose of anticancer herbs may be lowered. This depends on your expertise. If you feel unsure as to how to interface the antineoplastic herbs with a specific cytotoxic therapy, then treat only symptomatically for the 3 days prior to and 2 days after chemotherapy. Do not use antineoplastic herbs during the infusion period. Resume antineoplastic herbs after this time period. If you are confident in your under- standing of the conventional cytotoxic mecha- nism, then go ahead and use antineoplastics.

Because of the extreme immune suppression during high-dose chemotherapy there is concern on the part of conventional providers about infec- tion caused by herbal medicine that may have bacteria, molds, and other forms of contamina- tion. This is especially true in the treatment of leukemias where high-dose chemotherapy and transplantation are possible treatments. This may automatically preclude treatment with any form of alternative medicine. If you are trusted by your patient and their providers, you may be able to treat with herbal medicine. Granulated herbs that have been packaged in single doses and then irradiated may be a means by which you can provide a safe herbal product to your patient. Patients undergoing transplantation still eat and herbs are designated as food. Therefore, work to ensure a pure herbal product and build strong relationships with conventional medical providers in order to continue providing care to your patients.

When using crude herbs that are prepared by the patient it is extremely important that the patient calls you during or after the first time of preparing the herbal soup. Have them describe to you what exactly they have done in the cooking process. Improper cooking can change the dose and allow for contamination of cooked soups. Any possible molds that develop as part of storage are to be avoided. If there is any question regarding contamination, the herbal soup must be discarded. Monitor your patients carefully in this respect.

When in doubt about your patient’s ability to prepare soups use high-quality granulated herbs instead.

Do not allow patients to begin their herbal med- icine during the first days of chemotherapy when nausea is high, as they may acquire a habituated negative response to the herbs. This can occur even with the patient on antiemetic drugs. Wait until the nausea has subsided to begin herbal treatment.

All of the formulas in this book are prescribed according to a gram dosage. This dosing method can be applied to either crude herbs or granulated herbs according to the usual means by which each are prescribed. The overall daily dose in oncology is usually at least twice that of the regular dose. For example, the typical dose per day for a non-cancer patient is 9 g. The typical dose for a cancer patient is at least 18 g, twice the normal dose. It is not uncommon for the dose per day to be increased to four times the normal dose. You will notice that the amounts for some of the herbs in many formulas are extremely high. The goal of all formulas in this context is to provide a very high circulating blood level of phytochemi- cal materials over a constant period of time. This may mean that dosing three times per day may not be enough and dosing can be increased to five or six times per day. The schedule will rely upon the needs of the patient and their ability to absorb the herbs.

Use herbs supplied by a reputable pharmacist who can guarantee through batch assays that all of the herbs used for your patients are free of any form of contamination, including heavy metals, pesticides, bacteria, viruses, other biological con- taminants, and chemical contaminants. It is im- possible to guarantee that herbs are free of fungi or mold. Cooking will kill most spores and, there- fore, crude herbs are free of spores at the end of cooking. But if more than one dose is cooked at a time, then storing cooked herbs must be done carefully in order to prevent contamination. Gran- ulated herbs are less susceptible to contamination but are still at risk. In the case of a patient whose

immunity is low and for whom the issue of bio- logical contamination is of great concern, it may be best to supply the herbs in individual packs that have been irradiated. Herbs in cooked form can be purchased from various suppliers. How- ever, these cooked herbal decoctions are packaged in a hot liquid form in plastic bags, which may release xenoestrogenic and other chemical con- taminants. It is best, in my opinion, to avoid these prepared crude herb decoctions until the issue of plastic contamination can be resolved.

PREVENTION

No cancer is considered cured until there is a 5- year disease-free interval. In many cases, recur- rence will occur during the first 2 years after the end of conventional treatment. Therefore, it is immensely important that patients continue treat- ment with complementary medicine for at least 2 years after finishing conventional care. During this time of monitoring by conventional providers no interventions occur that help to rehabilitate function lost as a result of the cancer itself or as a result of cytotoxic treatment. Very little informa- tion is given about things the patient can do to prevent a recurrence of their cancer.

Complementary providers frequently become the primary providers of support and information in this phase of cancer surveillance. It is important to convince patients that their cancer treatment is not finished. Diet, sleep, exercise, happiness, and peace are all necessary components of health that need to become a part of their life in the long term. Continuing with Chinese medicine and possibly supplementation will contribute to their ability to remain disease-free. Each chapter of this book has information and formulas used to prevent recur- rence on each cancer type. The work to change the environment in which the cancer occurred contin- ues after cytotoxic treatment. It cannot be stated strongly enough how important this ongoing treatment is in terms of overall survival. One chapter of this book has been dedicated to general prevention.

References

19. Zhou Li (The Zhou Rituals). Compiled in the Qin Dynasty. 221–207 BCE.52.

20. In: Shuo Wen Jie Zi (Discussing characters and explaining words).

21. In: Zheng Zi Tong (A comprehensive discussion of the correct use of characters).

22. Wang Qing Ren. Yi Lin Gai Gao (Corrections of errors among physicians). 1830 ACE. People’s Health Publishing; 1985.

23. Kuwahara, Koei. Notes from Toyo Hari training, 1996.

24. Li Yan. Zhong Liu Lin Chuang Bei Yao (Essentials of clinical pattern identification of tumors). 2nd edn. Beijing: People’s Medical Publishing House; 1998.

25. Larre C. The liver. Paris: Institut Ricci; 1989. 26. Jarrett L. Nourishing destiny. Spirit Path

1998:241–244.

27. Jarrett L. Nourishing destiny. Spirit Path 1998:279– 290.

28. Sun Si Miao. Qian Jin Yao Fang (Presciptions worth a thousand gold pieces for emergencies). 652 ACE. People’s Health Publishing; 1982.

29. Cleavey S. Fluid physiology and pathology in tra- ditional Chinese medicine. London: Churchill Livingstone; 1995:167–168, 232–236.

30. Zhang Jing Yue. Jing Yue Yuan Shu (The complete works of Jing Yue). 1624 ACE. Shanghai Science and Technology Press; 1959.

31. Chao Yuan Fang. Zhu Bing Yuan Hou Lun (Gener- alised treatise on the etiology and symptomatology of disease). 610 ACE.

32. Huo Jinglun, ed. Treatment of pediatric diseases in traditional Chinese medicine. Academy Press (Xue Yuan); 1995:6–11.

33. Yu Rencun. Immune mechanism of Chinese materia medica in inhibiting cancer. Zhong Guo Zhong Liu (Chinese Journal of Oncology) 1993; 2:20–21. 34. Sun Yan. Results of double-blind clinical tests on

Ligustrin in promoting the immune effect. Zhong Guo Lin Chuang Xao Li Za Zhi (Chinese Journal of Clinical Pharmacology) 1990; 2:1–3.

35. Wang Jin Yuan. Shen bai pian zhi liao bai xi bao jian shao zheng de lin chuang yi ji shi yan yan jiu (Clin- ical and laboratory study of Sheng bai pain (Restore the White Pills) in the treatment of leukopenia). Zhong Yi Zha Zhi (Journal of Traditional Chinese Medicine) 1988; 1:32–53.

36. Shan BE. Chinese medicinal herb, Acanthopanax gracilistylus, extract induces cell cycle arrest of human tumor cells in vitro. Jpn J Cancer Res 2000; 91:383–389.

1. Silverburg E. Cancer statistics, 1995. American Cancer Society 1995; 40:9–26.

2. Dean M. Principles of molecular cell biology. In: DeVita VT, ed. Cancer: principles and practice of oncology. 3rd edn. Philadelphia: JB Lippincott; 1989. 3. Phillips RA. The genetic basis of cancer. In: Tannock IF, ed. The basic science of oncology. New York: Pergamon Press; 1987.

4. Minden MD. Oncogenes. In: Tannock IF, ed. The basic science of oncology. New York: Pergamon Press; 1987.

5. Roberts AB. Principles of molecular cell biology of cancer: growth factors related to transformation. In: DeVita VT, ed. Cancer: principles and practice of oncology. 3rd edn. Philadelphia: JB Lippincott; 1989:67–80.

6. Sager R. Tumor suppressor genes: the puzzle and the promise. Science 1990; 246:1406–1412.

7. Henshaw EC. The biology of cancer. In: Rubin P, ed. Clinical oncology. 7th edn. Philadelphia: WB Saun- ders; 1993:26.

8. Carson R. Silent spring. Boston: Houghton-Mifflin; 1962.

9. Epstein S. The carcinogenicity of heptachlor and chlordane. Sci Total Environ 1976; 6:103–154. 10. Infante PF. Blood dyscrasias and childhood tumors

and exposures to chlorinated hydrocarbon pesti- cides. Proceedings from the 14–19 June 1976 Con- ference on Women in the Workplace. Washington, DC: Society for Occupational and Environmental Health.

11. National Academy of the Sciences, National Research Council, Advisory Center on Toxicology, Pesticide Information Review and Evaluation Committee. An evaluation of the carcinogenicity of chlordane and heptachlor. Washington, DC October, 1977.

12. Hoy C. The truth about breast cancer. Boston: Stoddart; 1995.

13. Raloff J. Menstrual cycles may affect cancer risk. Science News, 7 January 1995.

14. Raloff J. Breast cancer: environmental factors. Lancet 1992; 339:904.

15. Zurhasen H. Viruses in human cancer. Science 1991; 254:1167–1172.

16. Miller EC. Mechanics of chemical carcinogenesis. Cancer 1981; 47:1055–1064.

17. Altman R. The cancer dictionary. Facts On File 1992:319–320.

18. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with onco- logic therapies. Altern Med Rev 1999; 4:304–329.

37. Chu DT. Immunotherapy with Chinese medicinal herbs. I. Immune restoration of local xenogeneic graft-versus-host reaction in cancer patients by frac- tionated Astragalus membranaceus in vitro. J Clin Lab Immunol 1988; 25:19–23.

38. Zhang J. Antitumor active protein-containing glycans from the Chinese mushroom Songshan ling zhi, Ganoderma tsugae mycelium. Biosci Biotechnol Biochem 1994; 58:1202–1205.

39. Wang G. Antitumor active polysaccharides from the Chinese mushroom Songshan lingzhi, the fruiting body of Ganoderma tsugae. Biosci Biotechnol Biochem 1993; 57:894–900.

40. Pecere T. Aloe-emodin is a new type of anti-cancer agent with selective activity against neuroectoder- mal tumors. Cancer Res 2000; 60:2800–2804. 41. Hever D. The role of nutrition in cancer prevention

and control. Oncology 1992; 6:9–14.

42. Duda RB. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol 1999; 72:230– 239.

43. Kim SE. Ginsenoside-Rs4, a new type of ginseng saponin concurrently induces apoptosis and selec- tively elevates protein levels of p53 and p21WAF1 in human hepatoma SK-HEP-1 cells. Eur J Cancer 1999; 35:507–511.

44. Kaminaga T. Inhibitory effects of lanastane-type triterpine acids, the components of Poria cocos, on tumor promotion by 12-0-tetra-decanoylphorbol- 13-acetate in two-stage carcinogenesis in mouse skin. Oncology 1996; 53:382–385.

45. Zheng S. Initial study on naturally occurring prod- ucts from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem Supplement 1997; 27:106–112.

46. Suzuki M. Antitumor and immunological activity of Lentinan in comparison with LPS. International J Immunopharm 1994; 16:463–468.

47. Sun Qingjing. Dan Shen Dui Gan Ai Zheng Sheng Wu Zhi Liao Xue (Current Biological Treatment of Cancer). Beijing: People’s Military Press; 1995:2. 48. Huang Lizhong. Yuan fa xing gan ai zhong yi zhi fa

de lin chuang yan jiu (Clinical study of primary liver cancer with Traditional Chinese Medicine methods). Hu Nan Zhong Yi Xue Yuan Xue Bao (J of Hunan TCM College) 1996; 16:14–17.

49. Pan Mingji. Cancer Treatment with Fu Zheng Pei Ben Principle. Fujian Science and Technology Pub- lishing House; 1992:18–19.

50. Gao Jin. Xioa shu wei ai pi xia yi zhi hou zhong liu fa gou zheng zhong xue ye liu bian xue de guan cha (Study of blood rheology during tumor develop- ment after hypodermic implantation of stomach cancer in mice). Zhong Hua Zhong Liu Za Zhi (Chinese J Oncol, 1989; 6:429.

51. Bi Liqi. Zhong yao tian hua fen dan bai dui hei se su xi bao ji xi bao zhou qi de ying xiang (Effect of the proteins in tian hua fen, R. trichosanthes, on melanocytes and the cell cycle. Zhong Guo Zhong Yi Xi Jie He Za Zhi (J Integ TCM and Western Med) 1998; 18:35–37.

52. Zhang Liping. Ku shen jian dui K562 xi bao zhu huo xing he xi bao zhouqi de ying xiang (Effect of matrine on the activity of the K562 cell strains and the cell cycle). Zhong Hua Zhong Liu Za Zhi (Chin Oncolo J), 1998; 20:328–329.

53. Kojima R, Fukushima S, Ueno A, et al. Antitumor activity of Leguminosae plant constituents. I. Anti- tumor activity of constituents of Sophora subpros- trata. Chem Pharm Bull 1970; 18:2555–2563. 54. Takagi S. Yakagaku Zasshi 1981; 101:657–659. 55. Huang KC. The pharmacology of Chinese herbs.

2nd edn. Boca Raton: CRC Press; 1999:478. 56. op. cit. 481.

57. op. cit. 480.

58. Huang Fuzhong. Ming Yi Zhi Zhang (A guide to famous physicians). 16th Century. People’s Health Publishing; 1982.

59. Wani MC. Taxus. J Am Chem Soc 1971; 93:2325–2326.

60. Zhang Yize. Zhong yao zai e xing zhong liu fang liao zhong de jian du zeng xiao zuo yong (The role of Chinese materia medica in increasing the effective- ness and reducing the toxicity of chemotherapy in the treatment of malignant tumors). Shandong Zhong Yi Za Zhi (Shandong J of TCM) 1998; 17:488–490.

61. Cao Guangwen. Xian Dai Ai Zheng Sheng Wu Zhi Liao Xue (Current Biological Treatment of Cancer). Beijing: People’s Military Press; 1995.

62. Liao Yuping. Tong qiao huo xue tang jia jian pei he fang liao zhi liao bi yan ai (Modified decoction for freeing the orifices and invigorating the blood combined with radiotherapy in the treatment of nasopharyngeal cancer. Zhong Xi Yi Jie He Za Zhi (J of Integrated TCM and Western Med) 1987; 7:214–216.

63. Zhang Daizhao. Zhang Dai Zhao Zhi Ai Jing Yan Ji Yao (A collection of Zhang Daizhao’s experiences in the treatment of cancer). Beijing: China Medicine and Pharmaceutical Publishing House; 2001. 64. Zhang Daizhao. E Xing Zhong Liu Fang Hua Zhong

Xi Zhi Liao (Chinese materia medica in the treat- ment of malignant tumors with chemotherapy and radiotherapy). Beijing: People’s Medical Publishing House; 2000.

65. Bensky D. Formulas and strategies. Seattle: Eastland Press; 1990:7–8.

Chapter

2